|
1
|
Costentin CE, Ferrone CR, Arellano RS,
Ganguli S, Hong TS and Zhu AX: Hepatocellular carcinoma with
macrovascular invasion: Defining the optimal treatment strategy.
Liver Cancer. 6:360–374. 2017. View Article : Google Scholar
|
|
2
|
Liu S, Miao R, Zhai M, Pang Q, Deng Y, Liu
S, Qu K, Liu C and Zhang J: Effects and related mechanisms of
serotonin on malignant biological behavior of hepatocellular
carcinoma via regulation of Yap. Oncotarget. 8:47412–47424.
2017.
|
|
3
|
Kim W, Khan SK, Liu Y, Xu R, Park O, He Y,
Cha B, Gao B and Yang Y: Hepatic Hippo signaling inhibits
protumoural microenvironment to suppress hepatocellular carcinoma.
Gut gutjnl-2017-314061. 2017.
|
|
4
|
Luo X, Liu Y, Feng W, Lei L, Du Y, Wu J
and Wang S: NUP37, a positive regulator of YAP/TEAD signaling,
promotes the progression of hepatocellular carcinoma. Oncotarget.
8:98004–98013. 2017. View Article : Google Scholar
|
|
5
|
Valero V III, Pawlik TM and Anders RA:
Emerging role of Hpo signaling and YAP in hepatocellular carcinoma.
J Hepatocell Carcinoma. 2:69–78. 2015.
|
|
6
|
Wright NT, Cannon BR, Zimmer DB and Weber
DJ: S100A1: Structure, function, and therapeutic potential. Curr
Chem Biol. 3:138–145. 2009.
|
|
7
|
Rocca PC, Brunelli M, Gobbo S, Eccher A,
Bragantini E, Mina MM, Ficarra V, Zattoni F, Zamò A and Pea M:
Diagnostic utility of S100A1 expression in renal cell neoplasms: An
immu-nohistochemical and quantitative RT-PCR study. Mod Pathol.
20:722–728. 2007. View Article : Google Scholar
|
|
8
|
Li G, Barthelemy A, Feng G, Gentil-Perret
A, Peoc’h M, Genin C and Tostain J: S100A1: A powerful marker to
differentiate chromophobe renal cell carcinoma from renal
oncocytoma. Histopathology. 50:642–647. 2007. View Article : Google Scholar
|
|
9
|
DeRycke MS, Andersen JD, Harrington KM,
Pambuccian SE, Kalloger SE, Boylan KL, Argenta PA and Skubitz AP:
S100A1 expression in ovarian and endometrial endometrioid
carcinomas is a prognostic indicator of relapse-free survival. Am J
Clin Pathol. 132:846–856. 2009. View Article : Google Scholar
|
|
10
|
Tian T, Li X, Hua Z, Ma J, Liu Z, Chen H
and Cui Z: S100A1 promotes cell proliferation and migration and is
associated with lymph node metastasis in ovarian cancer. Discov
Med. 23:235–245. 2017.
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
12
|
Wang T, Huo X, Chong Z, Khan H, Liu R and
Wang T: A review of S100 protein family in lung cancer. Clin Chim
Acta. 476:54–59. 2018. View Article : Google Scholar
|
|
13
|
Tong L, Lan W, Lim RR and Chaurasia SS:
S100A proteins as molecular targets in the ocular surface
inflammatory diseases. Ocul Surf. 12:23–31. 2014. View Article : Google Scholar
|
|
14
|
Wang G, Rudland PS, White MR and
Barraclough R: Interaction in vivo and in vitro of the
metastasis-inducing S100 protein, S100A4 (9Ka) with S100A1. J Biol
Chem. 275:11141–11146. 2000. View Article : Google Scholar
|
|
15
|
Wang G, Zhang S, Fernig DG,
Martin-Fernandez M, Rudland PS and Barraclough R: Mutually
antagonistic actions of S100A4 and S100A1 on normal and metastatic
phenotypes. Oncogene. 24:1445–1454. 2005. View Article : Google Scholar
|
|
16
|
Donato R, Sorci G and Giambanco I: S100A6
protein: Functional roles. Cell Mol Life Sci. 74:2749–2760. 2017.
View Article : Google Scholar
|
|
17
|
Fagerberg L, Hallström BM, Oksvold P,
Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S,
Danielsson A and Edlund K: Analysis of the human tissue-specific
expression by genome-wide integration of transcriptomics and
antibody-based proteomics. Mol Cell Proteomics. 13:397–406. 2014.
View Article : Google Scholar
|
|
18
|
Teratani T, Watanabe T, Kuwahara F,
Kumagai H, Kobayashi S, Aoki U, Ishikawa A, Arai K and Nozawa R:
Induced transcriptional expression of calcium-binding protein
S100A1 and S100A10 genes in human renal cell carcinoma. Cancer
Lett. 175:71–77. 2002. View Article : Google Scholar
|
|
19
|
Li G, Gentil-Perret A, Lambert C, Genin C
and Tostain J: S100A1 and KIT gene expressions in common subtypes
of renal tumours. Eur J Surg Oncol. 31:299–303. 2005. View Article : Google Scholar
|
|
20
|
Sviatoha V, Tani E, Kleina R, Sperga M and
Skoog L: Immunohistochemical analysis of the S100A1, S100B, CD44
and Bcl-2 antigens and the rate of cell proliferation assessed by
Ki-67 antibody in benign and malignant melanocytic tumours.
Melanoma Res. 20:118–125. 2010. View Article : Google Scholar
|
|
21
|
Cossu-Rocca P, Contini M, Brunelli M,
Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G and
Martignoni G: S-100A1 is a reliable marker in distinguishing
nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg
Pathol. 33:1031–1036. 2009. View Article : Google Scholar
|
|
22
|
Carvalho JC, Wasco MJ, Kunju LP, Thomas DG
and Shah RB: Cluster analysis of immunohistochemical profiles
delineates CK7, vimentin, S100A1 and C-kit (CD117) as an optimal
panel in the differential diagnosis of renal oncocytoma from its
mimics. Histopathology. 58:169–179. 2011. View Article : Google Scholar
|
|
23
|
Kuroda N, Kanomata N, Yamaguchi T, Imamura
Y, Ohe C, Sakaida N, Hes O, Michal M, Shuin T and Lee GH:
Immunohistochemical application of S100A1 in renal onco-cytoma,
oncocytic papillary renal cell carcinoma, and two variants of
chromophobe renal cell carcinoma. Med Mol Morphol. 44:111–115.
2011. View Article : Google Scholar
|
|
24
|
Yordanov A, Ivanov I, Popovska S, Dineva
T, Dimitrov T and Ivanova Z: Evaluation of the expression of S100A1
protein in serous, mucinous and endometroid ovarian carcinoma.
Akush Ginekol (Sofiia). 52:22–26. 2013.In Bulgarian.
|
|
25
|
Conner JR, Hirsch MS and Jo VY: HNF1β and
S100A1 are useful biomarkers for distinguishing renal oncocytoma
and chro-mophobe renal cell carcinoma in FNA and core needle
biopsies. Cancer Cytopathol. 123:298–305. 2015. View Article : Google Scholar
|
|
26
|
Hatoum D, Yagoub D, Ahadi A, Nassif NT and
McGowan EM: Annexin/S100A protein family regulation through
14ARF-53 activation: A role in cell survival and predicting
treatment outcomes in breast cancer. PLoS One. 12:e01699252017.
View Article : Google Scholar
|
|
27
|
Mencía N, Selga E, Rico I, de Almagro MC,
Villalobos X, Ramirez S, Adan J, Hernández JL, Noé V and Ciudad CJ:
Overexpression of S100A4 in human cancer cell lines resistant to
methotrexate. BMC Cancer. 10:2502010. View Article : Google Scholar
|
|
28
|
Tsuchiya M, Yamaguchi F, Shimamoto S,
Fujimoto T, Tokumitsu H, Tokuda M and Kobayashi R: Oxidized S100A4
inhibits the activation of protein phosphatase 5 through S100A1 in
MKN-45 gastric carcinoma cells. Int J Mol Med. 34:1713–1719. 2014.
View Article : Google Scholar
|
|
29
|
Tarabykina S, Kriajevska M, Scott DJ, Hill
TJ, Lafitte D, Derrick PJ, Dodson GG, Lukanidin E and Bronstein I:
Heterocomplex formation between metastasis-related protein S100A4
(Mts1) and S100A1 as revealed by the yeast two-hybrid system. FEBS
Lett. 475:187–191. 2000. View Article : Google Scholar
|
|
30
|
Watt KI, Harvey KF and Gregorevic P:
Regulation of tissue growth by the mammalian Hippo signaling
pathway. Front Physiol. 8:9422017. View Article : Google Scholar
|
|
31
|
Lin KC, Park HW and Guan KL: Regulation of
the Hippo pathway transcription factor TEAD. Trends Biochem Sci.
42:862–872. 2017. View Article : Google Scholar
|
|
32
|
Hong AW, Meng Z and Guan KL: The Hippo
pathway in intestinal regeneration and disease. Nat Rev
Gastroenterol Hepatol. 13:324–337. 2016. View Article : Google Scholar
|
|
33
|
Yimlamai D, Fowl BH and Camargo FD:
Emerging evidence on the role of the Hippo/YAP pathway in liver
physiology and cancer. J Hepatol. 63:1491–1501. 2015. View Article : Google Scholar
|
|
34
|
Li Y, Kong F, Shao Q, Wang R, Hu E, Liu J,
Jin C, He D and Xiao X: YAP expression and activity are suppressed
by S100A7 via 65/NFκB-mediated repression of ΔNp63. Mol Cancer Res.
15:1752–1763. 2017. View Article : Google Scholar
|
